โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 21 in last 7 days ๐ŸŽ Food: 1 in last 7 days ๐Ÿงธ Products: 52 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 1 hour ago โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 21 in last 7 days ๐ŸŽ Food: 1 in last 7 days ๐Ÿงธ Products: 52 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 1 hour ago
๐Ÿ›ก๏ธ EUSW
๐Ÿ‡ฌ๐Ÿ‡ง
๐Ÿ’Š

Poherdy

pertuzumab
Breast Neoplasms
โœ… Authorised Biosimilar
โœ…
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Early breast cancerPoherdy is indicated for use in combination with trastuzumab and chemotherapy in:- the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence- the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrenceMetastatic breast cancerPoherdy is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

โš ๏ธ Patient safety

No

โš ๏ธ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.